Merck & Co’s “Buy” Rating Reaffirmed at TheStreet (MRK)
Merck & Co (NYSE:MRK)‘s stock had its “buy” rating restated by investment analysts at TheStreet in a note issued to investors on Sunday, Analyst Ratings Network.com reports.
The analysts wrote, “Merck (MRK) has been reiterated by TheStreet Ratings as a buy with a ratings score of B+. The company’s strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income.”
Shares of Merck & Co (NYSE:MRK) opened at 46.54 on Friday. Merck & Co has a one year low of $40.02 and a one year high of $50.16. The stock’s 50-day moving average is $47.92 and its 200-day moving average is $46.68. The company has a market cap of $136.2 billion and a P/E ratio of 27.68. Merck & Co also was the target of some unusual options trading on Friday. Investors acquired 17,568 put options on the company. This is an increase of 214% compared to the average volume of 5,600 put options.
Merck & Co (NYSE:MRK) last announced its earnings results on Tuesday, July 30th. The company reported $0.84 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.82 by $0.02. The company had revenue of $11.01 billion for the quarter, compared to the consensus estimate of $11.22 billion. During the same quarter last year, the company posted $1.05 earnings per share. Merck & Co’s revenue was down 10.6% compared to the same quarter last year. Analysts expect that Merck & Co will post $3.47 EPS for the current fiscal year.
Several other analysts have also recently commented on the stock. Analysts at BMO Capital Markets cut their price target on shares of Merck & Co to $48.00 in a research note to investors on Thursday, October 17th. They now have a “market perform” rating on the stock. Separately, analysts at Sanford C. Bernstein downgraded shares of Merck & Co from an “outperform” rating to a “market perform” rating in a research note to investors on Monday, October 14th. They now have a $50.00 price target on the stock, down previously from $53.00. Finally, analysts at Jefferies Group downgraded shares of Merck & Co from a “buy” rating to a “hold” rating in a research note to investors on Friday, October 11th. They now have a $50.00 price target on the stock, down previously from $53.00. Two research analysts have rated the stock with a sell rating, eight have assigned a hold rating and seven have assigned a buy rating to the company. The company presently has an average rating of “Hold” and a consensus price target of $50.96.
Merck & Co, Inc (NYSE:MRK) is a global health care company that delivers health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products, which it markets directly and through its joint ventures.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.